Daiichi’s Quizartinib And The Quintessential 'Pazdur Moment'

 
• By Michael McCaughan

Daiichi Sankyo made a strong case to rebut US FDA’s concerns about the 'credibility' of a survival benefit reported for its refractory AML therapy quizartinib in front of the Oncologic Drugs Advisory Committee. Then Richard Pazdur spoke.

Richard Pazdur
He looks friendly enough, but sponsors should try to avoid getting into an ODAC with him. • Source: FDA photo by Michael J. Ermarth

More from US FDA Performance Tracker

More from Regulatory Trackers